Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Interest Expenses (2022 - 2025)

Coeptis Therapeutics Holdings (COEP) has 4 years of Interest Expenses data on record, last reported at $62610.0 in Q3 2025.

  • For Q3 2025, Interest Expenses rose 22.94% year-over-year to $62610.0; the TTM value through Sep 2025 reached $280518.0, down 15.33%, while the annual FY2024 figure was $396116.0, 267.85% up from the prior year.
  • Interest Expenses reached $62610.0 in Q3 2025 per COEP's latest filing, down from $67788.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $200505.0 in Q1 2024 and bottomed at $13832.0 in Q4 2023.
  • Average Interest Expenses over 4 years is $67828.6, with a median of $62610.0 recorded in 2025.
  • Peak YoY movement for Interest Expenses: crashed 89.8% in 2023, then soared 538.21% in 2024.
  • A 4-year view of Interest Expenses shows it stood at $135671.0 in 2022, then plummeted by 89.8% to $13832.0 in 2023, then soared by 468.46% to $78629.0 in 2024, then decreased by 20.37% to $62610.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $62610.0 in Q3 2025, $67788.0 in Q2 2025, and $71491.0 in Q1 2025.